Motexafin lutetium is a
texaphyrin, marketed as Antrin by Pharmacyclics Inc.
It is a photosensitiser for use in
photodynamic therapy to treat skin conditions and superficial cancers.
It has also been tested for use in
photoangioplasty (photodynamic treatment of diseased arteries).
It is photoactivated by 732 nm light which allows greater depth of penetration.
Clinical trials
Phase II clinical trials were in progress in 1999.
A phase I trial for
prostate cancer
Prostate cancer is cancer of the prostate. Prostate cancer is the second most common cancerous tumor worldwide and is the fifth leading cause of cancer-related mortality among men. The prostate is a gland in the male reproductive system that sur ...
reported in 2009.
References
Tetrapyrroles
Lutetium complexes
{{dermatologic-drug-stub